Six Years Is Two Plus Four: The Ban Where the Paper Weighs More Than the Drug
**সংক্ষিপ্ত উত্তর:** ইথিওপিয়ান ম্যারাথনার রুটি আগাকে ছয় বছরের নিষেধাজ্ঞা দিয়েছে অ্যান্টি-ডোপিং প্যানেল। এর দুই বছর নিষিদ্ধ পদার্থ মিথাইলপ্রেডনিসোলনের জন্য, চার বছর পরিবারের সদস্যের জোগাড় করা জাল প্রেসক্রিপশনে ট্যাম্পারিংয়ের জন্য। ১০ সেপ্টেম্বর থেকে নিষেধাজ্ঞা কার্যকর; মার্চের চীনা হাফ ম্যারাথনের ফল বাতিল। **মূল তথ্য:** - রুটি আগা, ইথিওপিয়া, বয়স ৩২; ২০১৯ টোকিও ম্যারাথন জয়ী এবং তিনটি ওয়ার্ল্ড ম্যারাথন মেজর রানার-আপ। - নিষেধাজ্ঞার মোট মেয়াদ ছয় বছর, যার চার বছর ট্যাম্পারিং ধারায় এবং দুই বছর নিষিদ্ধ পদার্থের ধারায়। - মিথাইলপ্রেডনিসোলন একটি গ্লুকোকর্টিকয়েড; ওয়াডা কাঠামোয় ইন-কম্পিটিশনে ইনজেকশন বা মুখে খাওয়ার রুটে নিষিদ্ধ। - প্রেসক্রিপশন দিয়েছিলেন পরিবারের সদস্য, যাঁর কোনো মেডিকেল রেজিস্ট্রেশন নেই; ক্লিনিক কাগজটি অস্বীকার করেছে। - মার্চের চীনা হাফ ম্যারাথনের শিরোনাম, প্রাইজমানি ও র্যাঙ্কিং পয়েন্ট বাতিল; ২০১৯ টোকিওর জয় অক্ষত। **সূত্র:** বিবিসি স্পোর্টের প্রতিবেদন ও অ্যাথলেটিক্স ইন্টিগ্রিটি ইউনিটের শাস্তি-সিদ্ধান্ত নথি; নিষেধাজ্ঞা কার্যকর ১০ সেপ্টেম্বর। **সম্ভাব্য ফলো-আপ প্রশ্ন:** প্রশ্ন: রুটি আগার ২০১৯ টোকিও ম্যারাথন জয় কি বাতিল হবে? উত্তর: না, এই সিদ্ধান্তে ২০১৯ টোকিওর শিরোনাম অক্ষত থাকছে, শুধু মার্চের হাফ ম্যারাথনের ফল বাতিল হবে। প্রশ্ন: ছয় বছর কেন, দুই বছর কেন নয়? উত্তর: নিষিদ্ধ পদার্থের ধারায় দুই বছর এবং ট্যাম্পারিংয়ের ধারায় চার বছর যোগ হওয়ায় মোট মেয়াদ ছয় বছর হয়েছে। প্রশ্ন: হাঁটুর চোটের ব্যাখ্যা থাকলে নিষেধাজ্ঞা এড়ানো যেত কি? উত্তর: প্রতিযোগিতার বাইরে নথিভুক্ত ও যথাযথ ক্লিয়ারেন্সসহ ইনজেকশন প্রতিরক্ষাসংগত হতে পারত, কিন্তু নথির শিকল ভেঙে যাওয়ায় প্রতিরক্ষাটি টেকেনি।
The prescription is a piece of paper. A clinic's name at the top, a date below it, a drug name, a seal. The person who produced it is a family member of the athlete, and that person holds no medical registration. Asked to explain, he said he had used an old prescription pad left over from a former workplace. The clinic named on the paper said flatly: we retired that pad years ago, the document is not ours.
I have spent forty-seven years auditing stopwatches — chasing the offence of folding hand-timed marks and electronic marks into a single column. This time the instrument is not a stopwatch. The instrument is a prescription pad, a clinic letterhead, and a TUE file that was never created. The principle holds: you audit the instrument before you audit the athlete. In this case the instrument broke, and it broke on the paper, not on the drug.
It sounds like one number, a six-year ban. It is not one number. It is two plus four.

Ruti Aga, Ethiopia, age thirty-two. Her marathon identity is clear enough: the 2026 Tokyo Marathon title, plus three runner-up finishes at World Marathon Major level. That record places her in the global fifteenth-to-twenty-fifth band of her generation — a consistent, podium-grade marathoner, but not the athlete the event was built around. Winning Tokyo is one thing; being the centre of the event is another measure entirely. The distinction matters, because the financial damage of a ban lands hardest at exactly this tier.
The trigger was a half marathon in China last March, which she won. The winning time was not published, and neither was the course. That is the first signal. A tier-three label road race, appearance-fee driven, far from Diamond League scrutiny — here the density of doping control is set by the local national anti-doping organisation and by Athletics Integrity Unit targeting, not by the race's commercial profile. For a mid-tier elite road runner this is the classic exposure zone: high fee, low surveillance.
The sample taken after that race returned methylprednisolone — a glucocorticoid, an anti-inflammatory, precisely the drug class a marathoner with a knee complaint is given. Under the WADA framework, glucocorticoids are prohibited in-competition, by injection or oral route. A properly documented out-of-competition injection is defensible; a detectable in-competition sample is not. Aga's explanation was a knee injury. The explanation is credible. The explanation is not the problem.
Her provisional suspension runs from 10 September, and the six-year ban is calculated from that date. This piece is being filed from a Chattogram desk — not from the mixed zone, not from a direct conversation with the athlete. By my own rule: this is a desk piece, and the evidence here is documentary.
Start with the chain on the paper, because that is where the actual event sits. A valid medical document has to satisfy four separate conditions: the prescriber's registration, the institution's valid letterhead, a record of the drug and dose, and where required a TUE or in-competition clearance document. In this case all four failed. No registration, a pad that was old and retired, a clinic that denied issuing it, no clearance paperwork at all. Had one condition held, this might have been a medical-records error; four failing together turned it into an investigation. That is a chain-of-custody failure on paper, not a pharmacology failure.
Now break the number. Four of the six years come from the tampering route, the remainder from the prohibited substance. Which means, in this case the false paper costs twice what the drug costs. Why? Because the modern anti-doping system is, functionally, a document system. Whereabouts filings, TUE certificates, sample collection chain-of-custody forms, laboratory documentation — the entire audit trail stands on paper. If paper can be forged, the trail has no floor. So the code prices forgery above ingestion. That is not a moral verdict, it is structural defence. In today's anti-doping, the document is the most valuable thing in the room and the most fragile.
Note one detail: the source material indicates no prior sanction history for Aga. Which means the entire increment above the base sanction came from a single cause — tampering. The repeat-offender clause did no work here. The four years are, on their own, the price of the paper.
And one uncomfortable fact: methylprednisolone is not a masking agent, not an anabolic steroid, not a chemical that turns the wheel faster. It is the everyday medicine of thousands of ordinary people. A substance that ordinary attracting a six-year sanction — that mismatch is itself the finding: the punishment is not for the drug, it is for the method.
An old spreadsheet of mine comes to mind here. In 2026 I got up at dawn for Tokyo and logged the qualification route of every Bangladeshi entry — wildcard or standard. The rule was: state the route before you state the result. The same rule applies here: state the paper before you state the drug. Aga's route was family-based, informal, and without a licensed team physician.
That is where the system point sits. The Ethiopian marathon pipeline — the altitude camps of the Addis Ababa, Sululta and Asella belt, the personal coach, the agent-managed race calendar — is world class in training. But does the agent's roster include a physician literate in TUEs? My suspicion is that in most cases it does not. I cannot prove that; the source names no coach and no medical team, so this is inference. But an athlete sourcing a prescription from a family member is an athlete operating outside an institutional medical channel, and that inference holds. The athlete is the output of a system; here the system failed at the level of medical staffing, not at the level of the drug.
My 2026 tagging method is doing different work this time. I borrowed frame-by-frame analysis from World Cup broadcast telestration and used it on archived 100m clips to estimate reaction times. Now the frames I am reading are the date on a prescription pad, the wording of a clinic statement, the phrasing of a denial. The method is the same — build the timeline, then write only what the timeline supports.
The financial arithmetic is harsher. The March half marathon result will be disqualified — title, prize money, ranking points, all of it. The 2026 Tokyo title is untouched by this decision. The record book keeps the trophy and deletes the paycheque. For an athlete whose income is dominated by appearance fees and podium bonuses rather than global endorsements, that race's entire earnings are clawed back. The remaining six years are career loss, not marginal loss.

Look at the age curve too. Six years starting at thirty-two means a return at thirty-eight. The marathon's extended peak window runs roughly twenty-seven to thirty-three, with outliers past thirty-five. On paper a late return is possible. In practice, six years outside competition and outside the testing system, outside the elite agent network, makes a return at Major level deeply improbable. That is not a prediction, it is a reading of the age curve.
One thing needs stating plainly. I am not casting suspicion on that Chinese half marathon. I am saying the commercial profile of a race does not determine where testing density sits. Where the fee is high and the samples are few, the mid-tier elite's risk is highest — that is a rule, not an allegation.
And four gaps remain on my desk: no race name, no winning time, no sample type (urine or blood), no year of decision. Without those four I cannot place the March performance on any list. Her 2026–19 marks sit inside the first-generation carbon-plate super-shoe dividend, and without course-level data that dividend cannot be deducted either. So I will not position the mark. If I do not have the clock, I do not write about the clock.
The headline says: six-year ban for a fake prescription issued by a family member. That is a family story, a betrayal story, a story with a little sentiment folded in. My reading runs the other way. The subject of this case is not a bad relative; the subject is a professional athlete who had no institutional medical infrastructure. In road running, medical infrastructure is compliance infrastructure. Without it, an ordinary knee injection can become a six-year event.
Second reading: the knee injury may well be real. It changes nothing. The investigation did not verify the knee, it verified the paper. That is my measure — keep two columns, the record book and the memory. 2026 Tokyo is not erased from the record book, and the audit of the paper must not quietly erase the memory.
And here is a condition rather than a verdict. If an appeal reduces or strips out the four-year tampering component, then the panel accepted the document as carelessness rather than fabrication. At that point this becomes a paperwork case, not a fraud case. Watch the appeal.
For the next Ethiopian marathoner, the question is not whether she has a doctor. The question is whether her agent's roster has a TUE-literate physician, and whether the federation will teach medical literacy as a module. The print beat shrank, so I built my own desk; the same work applies here — somebody has to keep the paper's accounts, because nobody else does. The clock will still run. The paper has to be right. How many elite road runners tonight are carrying a medical file that would survive four years of scrutiny?
